RSLS
Income statement / Annual
Last year (2023), ReShape Lifesciences Inc.'s total revenue was $8.68 M,
a decrease of 22.79% from the previous year.
In 2023, ReShape Lifesciences Inc.'s net income was -$11.39 M.
See ReShape Lifesciences Inc.’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
Operating Revenue |
$8.68 M
|
$11.24 M
|
$13.60 M
|
$11.30 M
|
$15.09 M
|
$606,710.00
|
$1.29 M
|
$786,660.00
|
$292,000.00
|
$0.00
|
Cost of Revenue |
$3.13 M |
$4.44 M |
$5.25 M |
$5.04 M |
$5.78 M |
$164,299.00 |
$936,386.00 |
$431,476.00 |
$125,000.00 |
$0.00 |
Gross Profit |
$5.55 M |
$6.80 M |
$8.35 M |
$6.26 M |
$9.31 M |
$442,411.00 |
$350,768.00 |
$355,184.00 |
$167,000.00 |
$0.00 |
Gross Profit Ratio |
0.64 |
0.61 |
0.61 |
0.55 |
0.62 |
0.73 |
0.27 |
0.45 |
0.57 |
0 |
Research and Development
Expenses |
$2.32 M
|
$2.54 M
|
$2.52 M
|
$3.50 M
|
$3.12 M
|
$5.72 M
|
$5.78 M
|
$5.17 M
|
$8.14 M
|
$11.03 M
|
General & Administrative
Expenses |
$10.32 M
|
$17.25 M
|
$24.41 M
|
$10.53 M
|
$17.22 M
|
$19.26 M
|
$25.98 M
|
$0.00
|
$0.00
|
$0.00
|
Selling & Marketing
Expenses |
$7.55 M
|
$14.09 M
|
$9.17 M
|
$4.69 M
|
$4.85 M
|
$5.24 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General &
Administrative Expenses |
$17.87 M
|
$31.34 M
|
$33.58 M
|
$15.22 M
|
$22.07 M
|
$19.26 M
|
$25.98 M
|
$17.98 M
|
$19.89 M
|
$14.56 M
|
Other Expenses |
$0.00 |
$11,000.00 |
$23.50 M |
$306,000.00 |
-$1.34 M |
-$10,643.00 |
-$652.00 |
$0.00 |
$0.00 |
$0.00 |
Operating Expenses |
$20.19 M |
$33.88 M |
$36.10 M |
$18.72 M |
$25.19 M |
$24.98 M |
$31.76 M |
$23.15 M |
$28.03 M |
$25.59 M |
Cost And Expenses |
$23.32 M |
$38.32 M |
$41.35 M |
$23.76 M |
$30.98 M |
$25.15 M |
$32.70 M |
$23.58 M |
$28.16 M |
$25.59 M |
Interest Income |
$0.00 |
$113,000.00 |
$832,000.00 |
$2.05 M |
$451,000.00 |
$0.00 |
$1,066.00 |
$5,837.00 |
$1,819.00 |
$3,331.00 |
Interest Expense |
$0.00 |
$113,000.00 |
$832,000.00 |
$2.05 M |
$451,000.00 |
$12,378.00 |
$3,874.00 |
$4.10 M |
$939,182.00 |
$530,222.00 |
Depreciation &
Amortization |
$154,000.00
|
$2.15 M
|
$1.97 M
|
$1.67 M
|
$894,000.00
|
$581,000.00
|
$330,000.00
|
$192,000.00
|
$188,606.00
|
$188,904.00
|
EBITDA |
-$14.49 M
|
-$24.93 M
|
-$60.62 M
|
-$18.10 M
|
-$17.22 M
|
-$36.97 M
|
-$34.39 M
|
-$19.51 M
|
-$27.68 M
|
-$25.40 M
|
EBITDA Ratio |
-1.67 |
-2.22 |
-2.04 |
-1.1 |
-1.14 |
-39.74 |
-24.4 |
-28.97 |
-103.54 |
0 |
Operating Income Ratio
|
-1.69
|
-2.41
|
-2.04
|
-1.1
|
-1.05
|
-63.53
|
-24.4
|
-28.98
|
-95.43
|
0
|
Total Other
Income/Expenses Net |
$3.30 M
|
-$4.68 M
|
-$12.17 M
|
-$9.35 M
|
-$50.64 M
|
-$167,731.00
|
-$1.37 M
|
-$565,217.00
|
$2.37 M
|
-$535,725.00
|
Income Before Tax |
-$11.34 M |
-$46.59 M |
-$62.04 M |
-$21.81 M |
-$75.10 M |
-$38.71 M |
-$36.13 M |
-$23.36 M |
-$25.50 M |
-$26.13 M |
Income Before Tax Ratio
|
-1.31
|
-4.15
|
-4.56
|
-1.93
|
-4.98
|
-63.81
|
-28.07
|
-29.7
|
-87.33
|
0
|
Income Tax Expense |
$52,000.00 |
-$380,000.00 |
-$106,000.00 |
-$181,000.00 |
-$893,000.00 |
-$3.45 M |
-$2.31 M |
$3.96 M |
-$2.56 M |
$347,096.00 |
Net Income |
-$11.39 M |
-$46.21 M |
-$61.93 M |
-$21.63 M |
-$74.21 M |
-$81.15 M |
-$33.82 M |
-$23.36 M |
-$25.50 M |
-$26.13 M |
Net Income Ratio |
-1.31 |
-4.11 |
-4.55 |
-1.91 |
-4.92 |
-133.76 |
-26.27 |
-29.7 |
-87.33 |
0 |
EPS |
-110.88 |
-6316.2 |
-16438.36 |
-48193.94 |
-137166.52 |
-370876.36 |
-176008.54 |
-481393.62 |
-132819.42 |
0 |
EPS Diluted |
-110.88 |
-6316.2 |
-16438.36 |
-48193.94 |
-137166.52 |
-370876.36 |
-176008.54 |
-481393.62 |
-132819.42 |
0 |
Weighted Average Shares
Out |
$102,699.00
|
$7,317.07
|
$3,767.62
|
$1,346.43
|
$1,623.00
|
$218.81
|
$192.14
|
$48.53
|
$191.98
|
$0.00
|
Weighted Average Shares
Out Diluted |
$102,699.00
|
$7,317.07
|
$3,767.62
|
$1,346.43
|
$1,623.00
|
$218.81
|
$192.14
|
$48.53
|
$191.98
|
$0.00
|
Link |
|
|
|
|
|
|
|
|
|
|